在宅医療における心不全患者の移行と転帰の改善 (I-TRANSFER-HF): タイプ 1 ハイブリッド有効性実施試験
This study is trying to improve the hospital-to-home transition for people with heart failure who receive home care services. The study will test an intervention called I-TRANSFER-HF, which differs from usual care by combining early home health nurse visits and outpatient medical appointments.
The study is interested in two questions:
- Is I-TRANSFER-HF better than usual care at preventing heart failure patients from returning to the hospital within 30 days?
- Are there parts of I-TRANSFER-HF that are easy or hard to implement in the real world?
The researchers will answer these questions by testing the intervention among pairs of hospitals and home health agencies across the country. During the study, the hospital-agency pairs will be asked to implement I-TRANSFER-HF. The researchers will then compare the results from before and after I-TRANSFER-HF was adopted. They will also interview people from these hospitals and agencies to see how I-TRANSFER-HF is being implemented under real-world conditions.
調査の概要
詳細な説明
The investigators' will test two hypotheses:
Hypothesis 1 (H1): Compared to usual care, adults with heart failure who receive the I-TRANSFER-HF intervention will have fewer 30-day readmissions, ED visits, and greater days at home. The four hospital-agency pairs will all begin the study with a baseline period of no intervention and then randomly selected to start the intervention phase at different points in time. Medicare claims data from each hospital-agency pair will be used to determine outcomes, and these data will be supplemented with national claims data for external controls not in the study to test the effectiveness of the I-TRANSFER-HF intervention.
Hypothesis 2 (H2): Compared to usual care, heart failure patients who receive I-TRANSFER-HF will have a higher proportion of timely first week HHC nursing visits (within 2 days of hospital discharge, plus 2 more) and outpatient visits (within 7-days of discharge). Given the rise of telemedicine, the study will test the association between the type of outpatient visit (in-person vs. virtual), its timing, and its association with outcomes. H2 requires conducting qualitative interviews with key stakeholders across the 4 hospital-agency pairs to identify barriers and facilitators that influence I-TRANSFER-HF's implementation. The study will assess the intervention's acceptability, feasibility, fidelity, and adaptation with interviews and Medicare claims data using a multi-methods approach and guided by the updated Consolidated Framework for Implementation Research (CFIR 2.0).
研究の種類
入学 (推定)
段階
- 適用できない
連絡先と場所
研究連絡先
- 名前:Madeline R Sterling, MD, MPH, MS
- 電話番号:6469625029
- メール:mrs9012@med.cornell.edu
研究場所
-
-
New York
-
New York、New York、アメリカ、10021
- 募集
- Weill Cornell Medicine
-
コンタクト:
- Madeline R Sterling, MD, MPH, MS
- 電話番号:646-962-5029
- メール:mrs9012@med.cornell.edu
-
主任研究者:
- Madeline R Sterling, MD, MPH, MS
-
New York、New York、アメリカ、10017
- 募集
- VNS Health Partners in Care
-
コンタクト:
- Kathy Bowles, PhD, RN,FAAN
- メール:bowles@nursing.upenn.edu
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Aim 1, Inclusion Criteria:
- Adults hospitalized for HF who transition from participating hospitals to their partner HHC agency during the study period.
Aim 1, Exclusion Criteria:
- Patients hospitalized for HF and discharged: home without HHC, or to an inpatient rehabilitation facility, skilled nursing facility, or hospice; patients with end stage renal disease on dialysis and those with left ventricular devices.
Aim 2, Inclusion Criteria:
- Healthcare professional involved in the transition of heart failure patients from the acute care setting (hospital) to HHC (home health care) agencies, and the implementation of the I-TRANSFER-HF at one of the four participating hospital-HHC dyads.
Aim 2, Exclusion Criteria:
- Healthcare professional not involved in the transition of heart failure patients from the acute care setting (hospital) to HHC (home health care) agencies, and the implementation of the I-TRANSFER-HF at one of the four participating hospital-HHC dyads.
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:ヘルスサービス研究
- 割り当て:ランダム化
- 介入モデル:順次割り当て
- マスキング:なし(オープンラベル)
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
実験的:I-TRANSFER-HF
This is a 1-year long intervention period when I-TRANSFER-HF is in operation. |
I-TRANSFER-HF is comprised of early and intensive HHC nurse visits and an outpatient visit within 7 days of discharge. Using a Hybrid Type 1, stepped wedge randomized trial design, we will test the effectiveness and implementation of I-TRANSFER-HF in partnership with 4 geographically diverse dyads of hospitals and HHC agencies ("hospital-HHC agency" dyads) across the US. |
|
介入なし:Standard of Care (usual care)
This is a baseline period of usual care (UC) with no intervention. |
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
All-cause 30-day hospital readmission
時間枠:30 days following post-Index HF Hospitalization
|
All-cause 30-day hospital readmission among adults hospitalized for heart failure who receive home health care after discharge and receive the I-TRANSFER-HF protocol compared to usual care, as assessed by Medicare claims |
30 days following post-Index HF Hospitalization
|
|
Number of Eligible patients
時間枠:12 months
|
Number of heart failure patients eligible to receive I-TRANSFER-HF as assessed by Medicare claims data |
12 months
|
|
Number of Eligible Patients Who Received Protocol Components
時間枠:12 months
|
Number of heart failure patients who received both components of I-TRANSFER-HF (front-loaded home health nurse visits and early outpatient medical follow-up), one, or none as assessed by Medicare claims data |
12 months
|
|
Modality of outpatient follow-up
時間枠:12 months
|
The modality of outpatient follow-up received (in-person vs. virtual visit) as assessed by Medicare claims data |
12 months
|
|
Timeliness of Post-Hospital Discharge Home Health Nursing Evaluation
時間枠:12 months
|
The timeliness of first-week nursing visits within 2 days of hospital discharge as assessed by Medicare claims data |
12 months
|
|
Timeliness of Post-Hospital Outpatient Follow-Up
時間枠:12 months
|
The timeliness of outpatient visits within 7 days of hospital discharge as assessed by Medicare claims data |
12 months
|
|
Feasibility of implementing I-TRANSFER-HF (Qualitative Interviews)
時間枠:30 days after intervention (year of intervention)
|
Feasibility will be assessed through qualitative interviews with site stakeholders |
30 days after intervention (year of intervention)
|
|
Feasibility of implementing I-TRANSFER-HF (Surveys)
時間枠:30 days after intervention (year of intervention)
|
Feasibility will be measured through the completion of the validated, 4-item, Feasibility of Intervention Measure (FIM). Items are measured on a 5-point Likert scale (Completely Disagree-Completely Agree). The score is calculated as the mean. The scale for this measure ranges from 4-20 with higher scores indicating greater perceived feasibility of the intervention. |
30 days after intervention (year of intervention)
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
All-cause 30-day ED visits
時間枠:30 days following post-Index heart failure Hospitalization.
|
All-cause 30-day emergency department visits among adults hospitalized for heart failure who receive home health care after discharge and receive the I-TRANSFER-HF protocol compared to usual care, as assessed by Medicare claims data |
30 days following post-Index heart failure Hospitalization.
|
|
Days at home among adults hospitalized for heart failure who receive home health care after discharge and receive the I-TRANSFER-HF protocol compared to usual care, as assessed by Medicare claims
時間枠:During a 12-month period (year of intervention)
|
Days at home will be calculated as 365 days minus the number of inpatient days in an acute care facility, an inpatient rehabilitation facility, a skilled nursing facility, or an inpatient hospice unit. |
During a 12-month period (year of intervention)
|
|
Acceptability of I-TRANSFER-HF - Qualitative Interviews
時間枠:30 days after intervention (year of intervention)
|
Acceptability will be assessed through qualitative interviews. |
30 days after intervention (year of intervention)
|
|
Acceptability of Intervention Measure for the I-TRANSFER-HF Study - Survey
時間枠:30 days after intervention (year of intervention)
|
Acceptability will be assessed through the 4-item, validated, Acceptability of Intervention Measure (AIM). Items are measured on a 5-point Likert scale (Completely Disagree-Completely Agree). The score is calculated as the mean. The scale for this measure ranges from 4-20 with higher scores indicating greater perceived acceptability of the intervention. |
30 days after intervention (year of intervention)
|
|
Fidelity of I-TRANSFER-HF (Participant-Completed)
時間枠:30 days after intervention (year of intervention)
|
Fidelity will be assessed by extent to which I-TRANSFER-HF is implemented by the study site teams. Fidelity will be measured using participant-completed fidelity checklists. These checklists will be developed during the implementation process. |
30 days after intervention (year of intervention)
|
|
Fidelity of I-TRANSFER-HF (Observational Ratings)
時間枠:30 days after intervention (year of intervention)
|
Fidelity will be assessed by extent to which I-TRANSFER-HF is implemented by the study site teams. Fidelity will be measured using observational fidelity ratings conducted by site champions. These checklists will be developed during the implementation process. |
30 days after intervention (year of intervention)
|
|
Adaptation of I-TRANSFER-HF
時間枠:30 days after intervention (year of intervention)
|
Adaptation will be assessed with qualitative interviews to document how the intervention was modified and refined during the study period. |
30 days after intervention (year of intervention)
|
協力者と研究者
協力者
捜査官
- 主任研究者:Madeline R Sterling, MD, MPH, MS、Weill Medical College of Cornell University
出版物と役立つリンク
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (推定)
研究の完了 (推定)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
キーワード
その他の研究ID番号
- 23-06026204
- R01HL169312 (米国 NIH グラント/契約)
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。